These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8112175)

  • 1. [Expression of mutant P53 gene protein product in human bladder carcinoma].
    Ye DW
    Zhonghua Wai Ke Za Zhi; 1993 Aug; 31(8):484-6. PubMed ID: 8112175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer.
    George B; Datar RH; Wu L; Cai J; Patten N; Beil SJ; Groshen S; Stein J; Skinner D; Jones PA; Cote RJ
    J Clin Oncol; 2007 Dec; 25(34):5352-8. PubMed ID: 18048815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relation between p53 overexpression and lymph node metastases in clinical stage t2 and t3a transitional cell bladder carcinoma.
    Uygur MC; Yaman I; Kutluay L; Altuğ U; Erol D
    J Exp Clin Cancer Res; 1999 Sep; 18(3):391-5. PubMed ID: 10606186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
    Saint F; Le Frere Belda MA; Quintela R; Hoznek A; Patard JJ; Bellot J; Popov Z; Zafrani ES; Abbou CC; Chopin DK; de Medina SG
    Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonal analysis of human recurrent superficial bladder cancer by immunohistochemistry of P53 and retinoblastoma proteins.
    Chern HD; Becich MJ; Persad RA; Romkes M; Smith P; Collins C; Li YH; Branch RA
    J Urol; 1996 Nov; 156(5):1846-9. PubMed ID: 8863629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder.
    Liu L; Zhu D; Gao R; Guo H
    Urol Int; 2008; 81(1):72-6. PubMed ID: 18645275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
    Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
    J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 gene mutation in recurrent superficial bladder cancer.
    Yoshimura I; Kudoh J; Saito S; Tazaki H; Shimizu N
    J Urol; 1995 May; 153(5):1711-5. PubMed ID: 7715016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
    Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
    Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
    Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
    Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of PCNA/cyclin, p53, C-erbB-2 versus histological grade in transitional cell carcinoma of urinary bladder].
    Yoshikawa H; Ikeuchi T; Iguchi H; Onodera Y; Kai Y
    Hinyokika Kiyo; 1995 Apr; 41(4):253-8. PubMed ID: 7785554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
    Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
    J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
    Dekairelle AF; Tombal B; Cosyns JP; Gala JL
    Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study.
    Salinas-Sánchez AS; Lorenzo-Romero JG; Giménez-Bachs JM; Sánchez-Sánchez F; Donate-Moreno MJ; Rubio-Del-Campo A; Hernández-Millán IR; Segura-Martín M; Atienzar-Tobarra M; Escribano-Martínez J
    Urol Oncol; 2008; 26(6):620-6. PubMed ID: 18367096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation analysis of the p53 tumor suppressor gene using paraffin-embedded specimens of human transitional cell carcinomas by the direct sequencing method.
    Masuda A; Kikuchi YY; Kawamura N
    Tokai J Exp Clin Med; 2000 Jun; 25(2):69-77. PubMed ID: 11127510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Proliferative activity and p53 expression in transitional cell carcinoma of the urinary bladder].
    Offner FA; Schäfer G; Hittmair A; Ofner D; Grünewald K; Weyrer K; Mattern D; Eberle J; Mikuz G; Feichtinger H
    Verh Dtsch Ges Pathol; 1993; 77():241-6. PubMed ID: 7511289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
    Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
    Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma.
    Tiguert R; Bianco FJ; Oskanian P; Li Y; Grignon DJ; Wood DP; Pontes JE; Sarkar FH
    J Urol; 2001 Dec; 166(6):2155-60. PubMed ID: 11696726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic implications of p53 gene mutations in bladder tumors.
    Lorenzo-Romero JG; Salinas-Sánchez AS; Giménez-Bachs JM; Sánchez-Sánchez F; Escribano-Martínez J; Segura-Martín M; Hernandez-Millán IR; Virseda-Rodríguez JA
    J Urol; 2003 Feb; 169(2):492-9. PubMed ID: 12544295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.